vs
ICU MEDICAL INC（ICUI）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
越洋钻探的季度营收约是ICU MEDICAL INC的1.9倍（$1.0B vs $540.7M），越洋钻探净利率更高（2.4% vs -2.9%，领先5.3%），越洋钻探同比增速更快（9.6% vs -14.1%），越洋钻探自由现金流更多（$321.0M vs $36.0M），过去两年越洋钻探的营收复合增速更高（16.9% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
ICUI vs RIG — 直观对比
营收规模更大
RIG
是对方的1.9倍
$540.7M
营收增速更快
RIG
高出23.7%
-14.1%
净利率更高
RIG
高出5.3%
-2.9%
自由现金流更多
RIG
多$285.0M
$36.0M
两年增速更快
RIG
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $1.0B |
| 净利润 | $-15.7M | $25.0M |
| 毛利率 | 37.5% | 42.0% |
| 营业利润率 | 1.0% | 23.0% |
| 净利率 | -2.9% | 2.4% |
| 营收同比 | -14.1% | 9.6% |
| 净利润同比 | 34.0% | 257.1% |
| 每股收益（稀释后） | $-0.63 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIRIG
| Q4 25 | $540.7M | $1.0B | ||
| Q3 25 | $537.0M | $1.0B | ||
| Q2 25 | $548.9M | $988.0M | ||
| Q1 25 | $604.7M | $906.0M | ||
| Q4 24 | $629.8M | $952.0M | ||
| Q3 24 | $589.1M | $948.0M | ||
| Q2 24 | $596.5M | $861.0M | ||
| Q1 24 | $566.7M | $763.0M |
净利润ICUIRIG
| Q4 25 | $-15.7M | $25.0M | ||
| Q3 25 | $-3.4M | $-1.9B | ||
| Q2 25 | $35.3M | $-938.0M | ||
| Q1 25 | $-15.5M | $-79.0M | ||
| Q4 24 | $-23.8M | $7.0M | ||
| Q3 24 | $-33.0M | $-494.0M | ||
| Q2 24 | $-21.4M | $-123.0M | ||
| Q1 24 | $-39.5M | $98.0M |
毛利率ICUIRIG
| Q4 25 | 37.5% | 42.0% | ||
| Q3 25 | 37.4% | 43.2% | ||
| Q2 25 | 37.9% | 39.4% | ||
| Q1 25 | 34.7% | 31.8% | ||
| Q4 24 | 36.1% | 39.2% | ||
| Q3 24 | 34.8% | 40.6% | ||
| Q2 24 | 34.8% | 38.0% | ||
| Q1 24 | 32.7% | 31.5% |
营业利润率ICUIRIG
| Q4 25 | 1.0% | 23.0% | ||
| Q3 25 | 2.6% | -163.1% | ||
| Q2 25 | 1.9% | -97.6% | ||
| Q1 25 | 2.1% | 7.1% | ||
| Q4 24 | 6.0% | 13.7% | ||
| Q3 24 | 1.4% | -51.2% | ||
| Q2 24 | 1.3% | -6.9% | ||
| Q1 24 | -1.9% | -0.4% |
净利率ICUIRIG
| Q4 25 | -2.9% | 2.4% | ||
| Q3 25 | -0.6% | -187.1% | ||
| Q2 25 | 6.4% | -94.9% | ||
| Q1 25 | -2.6% | -8.7% | ||
| Q4 24 | -3.8% | 0.7% | ||
| Q3 24 | -5.6% | -52.1% | ||
| Q2 24 | -3.6% | -14.3% | ||
| Q1 24 | -7.0% | 12.8% |
每股收益（稀释后）ICUIRIG
| Q4 25 | $-0.63 | $0.13 | ||
| Q3 25 | $-0.14 | $-2.00 | ||
| Q2 25 | $1.43 | $-1.06 | ||
| Q1 25 | $-0.63 | $-0.11 | ||
| Q4 24 | $-0.97 | $-0.14 | ||
| Q3 24 | $-1.35 | $-0.58 | ||
| Q2 24 | $-0.88 | $-0.15 | ||
| Q1 24 | $-1.63 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $620.0M |
| 总债务越低越好 | — | $5.2B |
| 股东权益账面价值 | $2.1B | $8.1B |
| 总资产 | $4.1B | $15.6B |
| 负债/权益比越低杠杆越低 | — | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资ICUIRIG
| Q4 25 | — | $620.0M | ||
| Q3 25 | — | $833.0M | ||
| Q2 25 | — | $377.0M | ||
| Q1 25 | — | $263.0M | ||
| Q4 24 | $308.6M | $560.0M | ||
| Q3 24 | $312.5M | $435.0M | ||
| Q2 24 | $302.6M | $475.0M | ||
| Q1 24 | $251.4M | $446.0M |
总债务ICUIRIG
| Q4 25 | — | $5.2B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $5.9B | ||
| Q1 25 | — | $5.9B | ||
| Q4 24 | — | $6.2B | ||
| Q3 24 | — | $6.5B | ||
| Q2 24 | — | $6.8B | ||
| Q1 24 | — | $6.8B |
股东权益ICUIRIG
| Q4 25 | $2.1B | $8.1B | ||
| Q3 25 | $2.1B | $8.1B | ||
| Q2 25 | $2.1B | $9.4B | ||
| Q1 25 | $2.0B | $10.2B | ||
| Q4 24 | $2.0B | $10.3B | ||
| Q3 24 | $2.0B | $10.2B | ||
| Q2 24 | $2.0B | $10.7B | ||
| Q1 24 | $2.1B | $10.5B |
总资产ICUIRIG
| Q4 25 | $4.1B | $15.6B | ||
| Q3 25 | $4.1B | $16.2B | ||
| Q2 25 | $4.1B | $17.8B | ||
| Q1 25 | $4.2B | $19.0B | ||
| Q4 24 | $4.2B | $19.4B | ||
| Q3 24 | $4.3B | $19.5B | ||
| Q2 24 | $4.3B | $20.3B | ||
| Q1 24 | $4.3B | $19.9B |
负债/权益比ICUIRIG
| Q4 25 | — | 0.64× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $321.0M |
| 自由现金流率自由现金流/营收 | 6.6% | 30.8% |
| 资本支出强度资本支出/营收 | 4.6% | 2.7% |
| 现金转化率经营现金流/净利润 | — | 13.96× |
| 过去12个月自由现金流最近4个季度 | $91.8M | $626.0M |
8季度趋势，按日历期对齐
经营现金流ICUIRIG
| Q4 25 | $60.6M | $349.0M | ||
| Q3 25 | $56.7M | $246.0M | ||
| Q2 25 | $11.2M | $128.0M | ||
| Q1 25 | $51.3M | $26.0M | ||
| Q4 24 | $40.2M | $206.0M | ||
| Q3 24 | $36.1M | $194.0M | ||
| Q2 24 | $82.0M | $133.0M | ||
| Q1 24 | $45.8M | $-86.0M |
自由现金流ICUIRIG
| Q4 25 | $36.0M | $321.0M | ||
| Q3 25 | $27.6M | $235.0M | ||
| Q2 25 | $-8.5M | $104.0M | ||
| Q1 25 | $36.7M | $-34.0M | ||
| Q4 24 | $16.1M | $177.0M | ||
| Q3 24 | $16.2M | $136.0M | ||
| Q2 24 | $62.5M | $49.0M | ||
| Q1 24 | $29.9M | $-169.0M |
自由现金流率ICUIRIG
| Q4 25 | 6.6% | 30.8% | ||
| Q3 25 | 5.1% | 22.9% | ||
| Q2 25 | -1.5% | 10.5% | ||
| Q1 25 | 6.1% | -3.8% | ||
| Q4 24 | 2.6% | 18.6% | ||
| Q3 24 | 2.7% | 14.3% | ||
| Q2 24 | 10.5% | 5.7% | ||
| Q1 24 | 5.3% | -22.1% |
资本支出强度ICUIRIG
| Q4 25 | 4.6% | 2.7% | ||
| Q3 25 | 5.4% | 1.1% | ||
| Q2 25 | 3.6% | 2.4% | ||
| Q1 25 | 2.4% | 6.6% | ||
| Q4 24 | 3.8% | 3.0% | ||
| Q3 24 | 3.4% | 6.1% | ||
| Q2 24 | 3.3% | 9.8% | ||
| Q1 24 | 2.8% | 10.9% |
现金转化率ICUIRIG
| Q4 25 | — | 13.96× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 29.43× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
